Ayyad Ahlam, Al-Horani Rami A
Division of Clinical and Administrative Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Gastroenterol Insights. 2023 Dec;14(4):420-430. doi: 10.3390/gastroent14040031. Epub 2023 Sep 28.
Hepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of hepatorenal syndrome. In cases where terlipressin therapy is accessible, the initial approach involves administering terlipressin alongside albumin. Terlipressin, a synthetic analog of vasopressin, boasts double the preference for vasopressin V1 receptors compared to V2 receptors. The FDA granted approval to terlipressin in September 2022, demonstrating its intrinsic activity, although a significant portion of its function arises from its transformation into lysine vasopressin. This article provides a comprehensive examination of terlipressin's various pharmacodynamic and pharmacokinetic facets, as well as its clinical utility, aiming to keep the scientific community well informed about its safe and efficient utilization.
肝肾综合征是急性或持续性肝病患者急性肾损伤的几种潜在触发因素之一。肾功能下降的性质导致了肝肾综合征两种变体的识别。在可获得特利加压素治疗的情况下，初始方法是将特利加压素与白蛋白一起给药。特利加压素是一种加压素的合成类似物，对血管加压素V1受体的偏好是V2受体的两倍。2022年9月，美国食品药品监督管理局（FDA）批准了特利加压素，证明了其内在活性，尽管其大部分功能来自于转化为赖氨酸加压素。本文全面审视了特利加压素的各种药效学和药代动力学方面，以及其临床效用，旨在让科学界充分了解其安全有效的使用方法。
